Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · COMPASS Pathways plc (CMPS)

Compass Pathways reports 26-week COMP006 Phase 3 data for COMP360 in depression

Positive Impact 4 of 5 other Written later

Compass Pathways reported 26-week results from the second Phase 3 COMP006 trial of COMP360 in treatment-resistant depression, saying they confirm rapid onset and durable response. The company said its rolling NDA submission is underway, with final submission expected in Q4 2026 and launch expected in the first half of 2027, subject to FDA approval and DEA rescheduling.

Key points

  • 39% of participants in the 25 mg arm reached a clinically meaningful MADRS reduction of at least 25% by Week 6 and maintained benefit through at least Week 26
  • COMP006 enrolled 581 dosed participants; serious adverse events were 6.3% in the 1 mg arm and 5.7% in the 25 mg arm over 26 weeks
  • Final NDA submission is expected in Q4 2026, with launch anticipated in the first half of 2027 if FDA approved

The filing

CompanyCOMPASS Pathways plc (CMPS)
Form8-K, current report
Filed with the SECJul 7, 2026, 6:33 AM ET
Accession number0001816590-26-000047

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.